Safety, Efficacy, and Biomarker Results of a Phase 1b/2 Study Combining the CD40 Agonist Mitazalimab with mFOLFIRINOX in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Results of the OPTIMIZE-1 Trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety, Efficacy, and Biomarker Results of a Phase 1b/2 Study Combining the CD40 Agonist Mitazalimab with mFOLFIRINOX in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC); Results of the OPTIMIZE-1 Trial

Published:2024 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Van Laethem Jean Luc,Borbath Ivan,Prenen Hans,Geboes Karen Paula,Lambert Aurélien,Mitry Emmanuel,Cassier Philippe,Blanc Jean-Frédéric,Pilla Lorenzo,Batlle Jaime Feliu,Rodríguez-Garrote Mercedes,Pazo-Cid Antonio,Gallego Inmaculada,Enell Smith Karin,Ellmark Peter,Pico de Coaña Yago,Ambarkhane Sumeet Vijay,Macarulla Teresa

Publisher

Elsevier BV

Reference30 articles.

1. Pancreatic cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;T Conroy;Ann Oncol,2023

2. Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors;P Rawla;World J Oncol,2019

3. Survival and prognostic factors of unresectable pancreatic cancer;J K Park;J Clin Gastroenterol,2008

4. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer;T Conroy;N Engl J Med,2011

5. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine;Von Hoff;N Engl J Med,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP